Post-mRNA COVID-19 Vaccination Myocarditis

Matta, Abhishek; Kallamadi, Rekha; Matta, Danielle; Bande, Dinesh

doi:10.12890/2021_002769

Cited by 9 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, 10 studies were excluded for the following reasons: inclusion of pediatric cases (n=7) [20] , [21] , [22] , [23] , [24] , [25] , [26] , diagnosis of multisystem inflammatory syndrome (n=1) [27] , analysis of incidence data of a pharmacovigilance database (n=1) [28] and opinion paper (n=1) [29] . Therefore, 39 studies were included; 37 of them [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] provided individual data of 86 participants, forming the pooled cohort. On the other hand, 2 observational studies [67] , [68] reported aggregated data of 43 patients.…”

Section: Resultsmentioning

confidence: 99%

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Bellos

Karageorgiou

Viskin

2022

Vaccine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Bellos

Karageorgiou

Viskin

2022

Vaccine

View full text Add to dashboard Cite

“…Further review identified a total of 57 studies reporting cases, case series, and summated case series of COVID‐19 vaccine‐associated myocarditis. 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 59 , 60 , 61 , 62 , 63 , …”

Section: Resultsmentioning

confidence: 99%

“…We identified 201 studies relevant to COVID‐19 vaccination and myocarditis. Further review identified a total of 57 studies reporting cases, case series, and summated case series of COVID‐19 vaccine‐associated myocarditis 8–65 . A total of 275 cases of COVID‐19 vaccine‐associated myocarditis were reported.…”

Section: Resultsmentioning

confidence: 99%

Myocarditis after COVID‐19 mRNA vaccination: A systematic review of case reports and case series

Park

Kaur

et al. 2022

Clinical Cardiology

View full text Add to dashboard Cite

Background The coronavirus disease of 2019 (COVID‐19) is a global pandemic with over 266 million cases and 5 million deaths worldwide. Anti‐COVID‐19 vaccinations have had exceptional success in subduing the incidence, prevalence, and disease severity of COVID‐19, but rare cases of myocarditis have been reported after COVID‐19 vaccinations. Hypothesis Myocarditis occurring after COVID‐19 mRNA vaccinations have distinguishable clinical characteristics. They usually have a favorable prognosis. Methods We performed a systematic literature search on PUBMED and MEDLINE database from inception to December 5, 2021. Studies were analyzed based on predetermined eligibility criteria. Results A total of 57 studies containing 275 cases of COVID‐19 vaccine‐associated myocarditis were catalogued. Mean age was 26.7 years and male to female ratio was 14:1. For 86.9% of patients, myocarditis occurred after the second dose. Average time to onset and length of hospitalization were 3.7 and 3.9 days, respectively. Prognosis was largely benign, but there was a 1.1% reported mortality. Chest pain (95.2%), elevation of troponin (100%), and ST elevation on electrocardiography (68.5%) were common. Nonsteroidal anti‐inflammatory drugs (81.4%) were the most used medication, followed by colchicine (33.1%). Conclusions Patients with COVID‐19 vaccine‐associated myocarditis are usually younger males presenting with chest pain 3–4 days after receiving their second dose of COVID vaccine. Diagnosis is made by exclusion of all other etiologies. Given significant population benefit from COVID‐19 vaccination, physicians should continue to encourage vaccination while remaining vigilant of the very rare occurrence of myocarditis following COVID‐19 vaccination.

show abstract

“…The initial search yielded 268 potentially relevant articles from which 75 unique studies involving 188 patients met eligibility criteria [ 16 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ,…”

Section: Resultsmentioning

confidence: 99%

Clinical Characteristics of Patients with Myocarditis following COVID-19 mRNA Vaccination: A Systematic Review and Meta-Analysis

Matar

Mansour

Nakanishi

et al. 2022

JCM

View full text Add to dashboard Cite

COVID-19 mRNA vaccinations have recently been implicated in causing myocarditis. Therefore, the primary aim of this systematic review and meta-analysis was to investigate the clinical characteristics of patients with myocarditis following mRNA vaccination. The secondary aims were to report common imaging and laboratory findings, as well as treatment regimes, in these patients. A literature search was performed from December 2019 to June 2022. Eligible studies reported patients older than 18 years vaccinated with mRNA, a diagnosis of myocarditis, and subsequent outcomes. Pooled mean or proportion were analyzed using a random-effects model. Seventy-five unique studies (patient n = 188, 89.4% male, mean age 18–67 years) were included. Eighty-six patients had Moderna vaccines while one hundred and two patients had Pfizer-BioNTech vaccines. The most common presenting symptoms were chest pain (34.5%), fever (17.1%), myalgia (12.4%), and chills (12.1%). The most common radiologic findings were ST-related changes on an electrocardiogram (58.7%) and hypokinesia on cardiac magnetic resonance imaging or echocardiography (50.7%). Laboratory findings included elevated Troponin I levels (81.7%) and elevated C-reactive protein (71.5%). Seven patients were admitted to the intensive care unit. The most common treatment modality was non-steroid anti-inflammatory drugs (36.6%) followed by colchicine (28.5%). This meta-analysis presents novel evidence to suggest possible myocarditis post mRNA vaccination in certain individuals, especially young male patients. Clinical practice must therefore take appropriate pre-cautionary measures when administrating COVID-19 mRNA vaccinations.

show abstract

Post-mRNA COVID-19 Vaccination Myocarditis

Cited by 9 publications

References 5 publications

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Myocarditis after COVID‐19 mRNA vaccination: A systematic review of case reports and case series

Clinical Characteristics of Patients with Myocarditis following COVID-19 mRNA Vaccination: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About